Bolt Biotherapeutics Initiates Phase II Clinical Studies of BDC-1001 in Patients with HER2-Positive Cancer

Bolt Biotherapeutics, Inc. announced that the first patients have been dosed in a Phase II dose-expansion clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate. The trial will explore BDC-1001 monotherapy treatment in three discreet cohorts for patients with HER2-positive colorectal, endometrial, and gastroesophageal cancers.